SlideShare uma empresa Scribd logo
1 de 7
This document is scheduled to be published in the
Federal Register on 05/05/2014 and available online at
http://federalregister.gov/a/2014-10202, and on FDsys.gov
BILLING CODE 4410-09-P
1
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA–378]
Controlled Substances: Adjustment to the Established 2014 Aggregate Production
Quota for Marijuana
AGENCY: Drug Enforcement Administration, Department of Justice.
ACTION: Notice with request for comments.
SUMMARY: This notice adjusts the established 2014 aggregate production quota for
marijuana, a schedule I controlled substance under the Controlled Substances Act.
DATES: Effective date: [INSERT DATE OF PUBLICATION IN THE FEDERAL
REGISTER]. Comment date: Interested persons may file written comments on this
notice in accordance with 21 CFR 1303.13. Electronic comments must be submitted and
written comments must be postmarked, on or before [INSERT DATE 30 DAYS AFTER
DATE OF PUBLICATION IN THE FEDERAL REGISTER]. Commenters should be
aware that the electronic Federal Docket Management System will not accept comments
after midnight Eastern Time on the last day of the comment period.
ADDRESSES: To ensure proper handling of comments, please reference “Docket No.
DEA–378” on all electronic and written correspondence. The DEA encourages that all
comments be submitted electronically through the Federal eRulemaking Portal which
provides the ability to type short comments directly into the comment field on the Web
page or attach a file for lengthier comments. Please go to http://www.regulations.gov
and follow the online instructions at that site for submitting comments. Paper comments
that duplicate electronic submissions are not necessary. Should you, however, wish to
2
submit written comments, in lieu of electronic comments, they should be sent via regular
or express mail to: Drug Enforcement Administration, Attention: DEA Federal Register
Representative/ODXL, 8701 Morrissette Drive, Springfield, Virginia 22152.
FOR FURTHER INFORMATION CONTACT: Ruth A. Carter, Office of Diversion
Control, Drug Enforcement Administration; Mailing Address: 8701 Morrissette Drive,
Springfield, Virginia 22152, Telephone: (202) 598–6812.
SUPPLEMENTARY INFORMATION:
Posting of Public Comments
Please note that all comments received in response to this docket are considered part
of the public record and will be made available for public inspection online at
http://www.regulations.gov. Such information includes personal identifying information
(such as your name, address, etc.) voluntarily submitted by the commenter.
The Freedom of Information Act (FOIA) applies to all comments received. If you
want to submit personal identifying information (such as your name, address, etc.) as part
of your comment, but do not want it to be made publicly available, you must include the
phrase “PERSONAL IDENTIFYING INFORMATION” in the first paragraph of your
comment. You must also place all of the personal identifying information you do not
want made publicly available in the first paragraph of your comment and identify what
information you want redacted. If you want to submit confidential business information
as part of your comment, but do not want it to be made publicly available, you must
include the phrase “CONFIDENTIAL BUSINESS INFORMATION” in the first
paragraph of your comment. You must also prominently identify the confidential
business information to be redacted within the comment. If a comment has so much
3
confidential business information that it cannot be effectively redacted, all or part of that
comment may not be made publicly available. Comments containing personal
identifying information or confidential business information identified as directed above
will be made publicly available in redacted form.
An electronic copy of this document is available at http://www.regulations.gov for
easy reference. If you wish to personally inspect the comments and materials received or
the supporting information the DEA used in preparing this action, these materials will be
available for public inspection by appointment. To arrange a viewing, please see the “For
Further Information Contact” paragraph above.
Pursuant to 21 CFR 1303.13, any interested person may submit written comments on
or objections to this notice. Based on comments received in response to this notice, the
Administrator may hold a public hearing on one or more issues raised in the comments
and objections filed. In the event the Administrator decides to hold such a hearing, the
Administrator shall publish notice of the hearing in the Federal Register. After
consideration of any comments or objections, or after a hearing, if one is held, the
Administrator shall issue and publish in the Federal Register a notice regarding the
adjustment to the established 2014 aggregate production quota for marijuana.1
Legal Authority
The Drug Enforcement Administration (DEA) implements and enforces titles II and
III of the Comprehensive Drug Abuse Prevention and Control Act of 1970, as amended.
Titles II and III are referred to as the “Controlled Substances Act” and the “Controlled
Substances Import and Export Act,” respectively, and are collectively referred to as the
1
Note that "marihuana" is the spelling originally used in the Controlled Substances Act (CSA). This
document uses the spelling that is more common in current usage, "marijuana."
4
“Controlled Substances Act” or the “CSA” for the purpose of this action. 21 U.S.C. 801–
971. The DEA publishes the implementing regulations for these statutes in title 21 of the
Code of Federal Regulations (CFR), parts 1300 to 1321. The CSA and its implementing
regulations are designed to prevent, detect, and eliminate the diversion of controlled
substances and listed chemicals into the illicit market while providing for the legitimate
medical, scientific, research, and industrial needs of the United States. Controlled
substances have the potential for abuse and dependence and are controlled to protect the
public health and safety.
Section 306 of the CSA (21 U.S.C. 826) requires the Attorney General to establish
aggregate production quotas for each basic class of controlled substance listed in
schedules I and II each year. The Attorney General has delegated this authority under 21
U.S.C. 826 to the Administrator of the DEA, 28 CFR 0.100.
Background
The DEA established the initial 2014 aggregate production quotas and assessments
for annual need on September 9, 2013 (78 FR 55099). The notice stipulated that, as
provided for in 21 CFR 1303.13, all aggregate production quotas and assessments for
annual need are subject to adjustment.
Analysis for Adjusting the Established 2014 Aggregate Production Quota for
Marijuana Effective on the Date of Publication
In determining to adjust the aggregate production quota, the DEA takes into
consideration, among other factors, the relevant scientific and research needs of the
United States. 21 U.S.C. 826; 21 CFR 1303.13(b)(5).
5
The National Institute on Drug Abuse (NIDA) is a component of the National
Institutes of Health and the U.S. Department of Health and Human Services, and it
oversees the cultivation, production and distribution of research-grade marijuana on
behalf of the United States Government, pursuant to the Single Convention on Narcotic
Drugs (March 30, 1961, 18 UST 1407). NIDA recently notified the DEA that it required
additional supplies of marijuana to be manufactured in 2014 to provide for current and
anticipated research efforts involving marijuana. Specifically, NIDA stated that 600
kilograms is necessary to be manufactured in 2014.
The DEA was unaware of NIDA’s additional need at the time the initial aggregate
production quota for marijuana was established in September 2013.
The aggregate production quota for marijuana should be increased in order to provide
a continuous and uninterrupted supply of marijuana in support of DEA-registered
researchers who are approved by the Federal Government to utilize marijuana in their
research protocols.
In the event the established aggregate production quota is increased, DEA regulations
require general notice of the adjustment prior to adjusting the quota. 21 CFR 1303.13(c).
Due to the manufacturing process unique to marijuana, including the length of time and
conditions necessary to propagate and process the substance for distribution in 2014, it is
necessary to adjust the initial, established 2014 aggregate production quota for marijuana
as soon as practicable. Accordingly, the Administrator finds good cause to adjust the
aggregate production quota for marijuana before accepting written comments from
interested persons or holding a public hearing, pursuant to 21 CFR 1303.13(c). More
specifically, the Administrator finds, based on NIDA's aforementioned submission to
6
DEA, that it is in the public interest to adjust the aggregate production quota immediately
to ensure that the cultivation of marijuana to meet NIDA's anticipated needs to supply
researchers can proceed within the current grow cycle. For this same reason, the
Administrator finds that delaying the adjustment to the aggregate production quota for
marijuana until after the comment period would be impracticable. Any such comments
shall be considered if submitted in accordance with the procedures described herein.
In issuing this adjustment, the DEA has taken into account the criteria that the DEA is
required to consider in accordance with 21 CFR 1303.13(b). The DEA determines
whether to adjust the aggregate production quotas for basic classes of schedule I and II
controlled substances by considering: (1) changes in demand for the basic class, changes
in the national rate of net disposal for the class, and changes in the rate of net disposal by
the registrants holding individual manufacturing quotas for the class; (2) whether any
increased demand or changes in the national or individual rates of net disposal are
temporary, short term, or long term; (3) whether any increased demand can be met
through existing inventories, increased individual manufacturing quotas, or increased
importation, without increasing the aggregate production quota; (4) whether any
decreased demand will result in excessive inventory accumulation by all persons
registered to handle the class; and (5) other factors affecting the medical, scientific,
research, and industrial needs of the United States and lawful export requirements, as the
Administrator finds relevant.
Based on the above, the Administrator adjusts the established 2014 aggregate
production quota for marijuana, to be manufactured in the United States in 2014 to
provide for the estimated scientific, research, and industrial needs of the United States,
7
and the establishment and maintenance of reserve stocks, expressed in grams of
anhydrous acid or base, as follows:
Basic Class-Schedule I
Previously Established
2014 Quota
Adjusted 2014 Quota
Marijuana 21,000 g 650,000 g
Dated: April 29, 2014.
Michele M. Leonhart,
Administrator.
[FR Doc. 2014-10202 Filed 05/02/2014 at 8:45 am; Publication Date: 05/05/2014]

Mais conteúdo relacionado

Mais procurados

Mais procurados (17)

Cia 2011-0004-0001
Cia 2011-0004-0001Cia 2011-0004-0001
Cia 2011-0004-0001
 
lawsuit against NSA
lawsuit against NSAlawsuit against NSA
lawsuit against NSA
 
Cannabis Corruption in New Mexico - Will the Fed's Jump In?
Cannabis Corruption in New Mexico - Will the Fed's Jump In?Cannabis Corruption in New Mexico - Will the Fed's Jump In?
Cannabis Corruption in New Mexico - Will the Fed's Jump In?
 
Gauhati hc display 2021-08-20t114832872-1-398963
Gauhati hc display 2021-08-20t114832872-1-398963Gauhati hc display 2021-08-20t114832872-1-398963
Gauhati hc display 2021-08-20t114832872-1-398963
 
New guidelines and laws for medical cannabis
New guidelines and laws for medical cannabisNew guidelines and laws for medical cannabis
New guidelines and laws for medical cannabis
 
Еxhibit
ЕxhibitЕxhibit
Еxhibit
 
6200 exhibit-ab-20201102-15
6200 exhibit-ab-20201102-156200 exhibit-ab-20201102-15
6200 exhibit-ab-20201102-15
 
The Florida Medical Marijuana Market is About to Go Hyper Growth!
The Florida Medical Marijuana Market is About to Go Hyper Growth!The Florida Medical Marijuana Market is About to Go Hyper Growth!
The Florida Medical Marijuana Market is About to Go Hyper Growth!
 
The DEA is Asking for More Marijuana and Mushrooms in 2022 for Research
The DEA is Asking for More Marijuana and Mushrooms in 2022 for ResearchThe DEA is Asking for More Marijuana and Mushrooms in 2022 for Research
The DEA is Asking for More Marijuana and Mushrooms in 2022 for Research
 
21st Century Approach to Regulating Cannabis
21st Century Approach to Regulating Cannabis21st Century Approach to Regulating Cannabis
21st Century Approach to Regulating Cannabis
 
The UAE to Relax Cannabis Laws Starting in 2022
The UAE to Relax Cannabis Laws Starting in 2022The UAE to Relax Cannabis Laws Starting in 2022
The UAE to Relax Cannabis Laws Starting in 2022
 
Senate COVID-19 spending bill and more
Senate COVID-19 spending bill and moreSenate COVID-19 spending bill and more
Senate COVID-19 spending bill and more
 
Business with medical cannabis
Business with medical cannabisBusiness with medical cannabis
Business with medical cannabis
 
Federal Register - Oct 22, 2015 - EPA 40 CFR Part 98 - Greenhouse Gas Reporti...
Federal Register - Oct 22, 2015 - EPA 40 CFR Part 98 - Greenhouse Gas Reporti...Federal Register - Oct 22, 2015 - EPA 40 CFR Part 98 - Greenhouse Gas Reporti...
Federal Register - Oct 22, 2015 - EPA 40 CFR Part 98 - Greenhouse Gas Reporti...
 
Guidelines to suo moto disclosure under section 4 of the RTI ACT
Guidelines to suo moto disclosure under section 4 of the RTI ACTGuidelines to suo moto disclosure under section 4 of the RTI ACT
Guidelines to suo moto disclosure under section 4 of the RTI ACT
 
MARCUSA California Cannabis Emergency Regulations - Accounting, Tax and Recor...
MARCUSA California Cannabis Emergency Regulations - Accounting, Tax and Recor...MARCUSA California Cannabis Emergency Regulations - Accounting, Tax and Recor...
MARCUSA California Cannabis Emergency Regulations - Accounting, Tax and Recor...
 
Irc sec. 280 e memo j
Irc sec. 280 e memo   jIrc sec. 280 e memo   j
Irc sec. 280 e memo j
 

Destaque

02 37-2013-00058302-cu-bc-ctl roa-33-11-05-13_reply_to_opposition_of_notice...
02   37-2013-00058302-cu-bc-ctl roa-33-11-05-13_reply_to_opposition_of_notice...02   37-2013-00058302-cu-bc-ctl roa-33-11-05-13_reply_to_opposition_of_notice...
02 37-2013-00058302-cu-bc-ctl roa-33-11-05-13_reply_to_opposition_of_notice...
Norman Gates
 
Trtc stock scammers
Trtc stock scammersTrtc stock scammers
Trtc stock scammers
Norman Gates
 
02 37-2013-00058302-cu-bc-ctl roa-33-11-05-13_reply_to_opposition_of_notice...
02   37-2013-00058302-cu-bc-ctl roa-33-11-05-13_reply_to_opposition_of_notice...02   37-2013-00058302-cu-bc-ctl roa-33-11-05-13_reply_to_opposition_of_notice...
02 37-2013-00058302-cu-bc-ctl roa-33-11-05-13_reply_to_opposition_of_notice...
Norman Gates
 
01 37-2013-00058302-cu-bc-ctl roa-24-10-28-13_opposition_other_to_plaintiff...
01   37-2013-00058302-cu-bc-ctl roa-24-10-28-13_opposition_other_to_plaintiff...01   37-2013-00058302-cu-bc-ctl roa-24-10-28-13_opposition_other_to_plaintiff...
01 37-2013-00058302-cu-bc-ctl roa-24-10-28-13_opposition_other_to_plaintiff...
Norman Gates
 

Destaque (20)

Mjna 2013
Mjna 2013Mjna 2013
Mjna 2013
 
Cbd ca2
Cbd ca2Cbd ca2
Cbd ca2
 
Fitzgerald report 1953
Fitzgerald report 1953Fitzgerald report 1953
Fitzgerald report 1953
 
02 37-2013-00058302-cu-bc-ctl roa-33-11-05-13_reply_to_opposition_of_notice...
02   37-2013-00058302-cu-bc-ctl roa-33-11-05-13_reply_to_opposition_of_notice...02   37-2013-00058302-cu-bc-ctl roa-33-11-05-13_reply_to_opposition_of_notice...
02 37-2013-00058302-cu-bc-ctl roa-33-11-05-13_reply_to_opposition_of_notice...
 
Us6630507
Us6630507Us6630507
Us6630507
 
Hemp shield
Hemp shieldHemp shield
Hemp shield
 
200313942 study-links-oxidative-stress-induced-mitochondrial-dysfunction-to-a...
200313942 study-links-oxidative-stress-induced-mitochondrial-dysfunction-to-a...200313942 study-links-oxidative-stress-induced-mitochondrial-dysfunction-to-a...
200313942 study-links-oxidative-stress-induced-mitochondrial-dysfunction-to-a...
 
Marijuana banking
Marijuana bankingMarijuana banking
Marijuana banking
 
Us20120311744
Us20120311744Us20120311744
Us20120311744
 
420 Investor, Alan Brochstein CFA
420 Investor, Alan Brochstein CFA420 Investor, Alan Brochstein CFA
420 Investor, Alan Brochstein CFA
 
FDA Tobacco Industry
FDA Tobacco IndustryFDA Tobacco Industry
FDA Tobacco Industry
 
Trtc stock scammers
Trtc stock scammersTrtc stock scammers
Trtc stock scammers
 
Terra Tech Corp. Edible Garden Issue June 12, 2014
Terra Tech Corp. Edible Garden Issue June 12, 2014Terra Tech Corp. Edible Garden Issue June 12, 2014
Terra Tech Corp. Edible Garden Issue June 12, 2014
 
420INVESTOR Blog - Trade Alerts
420INVESTOR Blog - Trade Alerts420INVESTOR Blog - Trade Alerts
420INVESTOR Blog - Trade Alerts
 
Terra Tech Corp. Edible Garden Issue August 14, 2014
Terra Tech Corp. Edible Garden Issue August 14, 2014Terra Tech Corp. Edible Garden Issue August 14, 2014
Terra Tech Corp. Edible Garden Issue August 14, 2014
 
Dahlia's Law - Edibles List
Dahlia's Law - Edibles ListDahlia's Law - Edibles List
Dahlia's Law - Edibles List
 
Us20100286993
Us20100286993Us20100286993
Us20100286993
 
02 37-2013-00058302-cu-bc-ctl roa-33-11-05-13_reply_to_opposition_of_notice...
02   37-2013-00058302-cu-bc-ctl roa-33-11-05-13_reply_to_opposition_of_notice...02   37-2013-00058302-cu-bc-ctl roa-33-11-05-13_reply_to_opposition_of_notice...
02 37-2013-00058302-cu-bc-ctl roa-33-11-05-13_reply_to_opposition_of_notice...
 
dsadsdsdsdsdsdsdsdsdsdsdsdsdsds
dsadsdsdsdsdsdsdsdsdsdsdsdsdsdsdsadsdsdsdsdsdsdsdsdsdsdsdsdsds
dsadsdsdsdsdsdsdsdsdsdsdsdsdsds
 
01 37-2013-00058302-cu-bc-ctl roa-24-10-28-13_opposition_other_to_plaintiff...
01   37-2013-00058302-cu-bc-ctl roa-24-10-28-13_opposition_other_to_plaintiff...01   37-2013-00058302-cu-bc-ctl roa-24-10-28-13_opposition_other_to_plaintiff...
01 37-2013-00058302-cu-bc-ctl roa-24-10-28-13_opposition_other_to_plaintiff...
 

Semelhante a DEA - More Marijuana

Cdc revises medical screening of aliens cdc 15-0623
Cdc revises medical screening of aliens cdc 15-0623Cdc revises medical screening of aliens cdc 15-0623
Cdc revises medical screening of aliens cdc 15-0623
RepentSinner
 
THE MEDICINE SHOPPE V. LORETTA LYNCH, ETAL. PHARMACISTS A.docx
THE MEDICINE SHOPPE V. LORETTA LYNCH, ETAL. PHARMACISTS A.docxTHE MEDICINE SHOPPE V. LORETTA LYNCH, ETAL. PHARMACISTS A.docx
THE MEDICINE SHOPPE V. LORETTA LYNCH, ETAL. PHARMACISTS A.docx
oreo10
 

Semelhante a DEA - More Marijuana (20)

Indiana-hemp-AG-opinion-lawsuit (1).pdf
Indiana-hemp-AG-opinion-lawsuit (1).pdfIndiana-hemp-AG-opinion-lawsuit (1).pdf
Indiana-hemp-AG-opinion-lawsuit (1).pdf
 
Hydraulic Fracturing Chemicals and Mixtures; Advance Notice of Proposed Rulem...
Hydraulic Fracturing Chemicals and Mixtures; Advance Notice of Proposed Rulem...Hydraulic Fracturing Chemicals and Mixtures; Advance Notice of Proposed Rulem...
Hydraulic Fracturing Chemicals and Mixtures; Advance Notice of Proposed Rulem...
 
Cdc revises medical screening of aliens cdc 15-0623
Cdc revises medical screening of aliens cdc 15-0623Cdc revises medical screening of aliens cdc 15-0623
Cdc revises medical screening of aliens cdc 15-0623
 
Marijuana, Opioids and State Laws – What HR Teams Need to Know
Marijuana, Opioids and State Laws – What HR Teams Need to KnowMarijuana, Opioids and State Laws – What HR Teams Need to Know
Marijuana, Opioids and State Laws – What HR Teams Need to Know
 
FDA Drug Approval Regulations & Safety
FDA Drug Approval Regulations & SafetyFDA Drug Approval Regulations & Safety
FDA Drug Approval Regulations & Safety
 
Nouvelles recommandations de la FDA sur la sécurité informatique des fabrican...
Nouvelles recommandations de la FDA sur la sécurité informatique des fabrican...Nouvelles recommandations de la FDA sur la sécurité informatique des fabrican...
Nouvelles recommandations de la FDA sur la sécurité informatique des fabrican...
 
The FDA's Response to COVID - 19
The FDA's Response to COVID - 19The FDA's Response to COVID - 19
The FDA's Response to COVID - 19
 
HIGHLIGHTED: Dissemination of Patient-Specific Information from Devices by De...
HIGHLIGHTED: Dissemination of Patient-Specific Information from Devices by De...HIGHLIGHTED: Dissemination of Patient-Specific Information from Devices by De...
HIGHLIGHTED: Dissemination of Patient-Specific Information from Devices by De...
 
THE MEDICINE SHOPPE V. LORETTA LYNCH, ETAL. PHARMACISTS A.docx
THE MEDICINE SHOPPE V. LORETTA LYNCH, ETAL. PHARMACISTS A.docxTHE MEDICINE SHOPPE V. LORETTA LYNCH, ETAL. PHARMACISTS A.docx
THE MEDICINE SHOPPE V. LORETTA LYNCH, ETAL. PHARMACISTS A.docx
 
Hatch waxman act and paragraph iv litigations
Hatch waxman act and paragraph iv litigationsHatch waxman act and paragraph iv litigations
Hatch waxman act and paragraph iv litigations
 
Global Submission Of IND, ANDA & NDA.pptx
Global Submission Of IND, ANDA & NDA.pptxGlobal Submission Of IND, ANDA & NDA.pptx
Global Submission Of IND, ANDA & NDA.pptx
 
DEA Hit with Another Cannabis Lawsuit
DEA Hit with Another Cannabis LawsuitDEA Hit with Another Cannabis Lawsuit
DEA Hit with Another Cannabis Lawsuit
 
Scientists Sue the DEA over Marijuana Research, Again!
Scientists Sue the DEA over Marijuana Research, Again!Scientists Sue the DEA over Marijuana Research, Again!
Scientists Sue the DEA over Marijuana Research, Again!
 
Generic Drug Labeling Proposed Rule: The Generic Drug Industry Perspective
Generic Drug Labeling Proposed Rule:  The Generic Drug Industry PerspectiveGeneric Drug Labeling Proposed Rule:  The Generic Drug Industry Perspective
Generic Drug Labeling Proposed Rule: The Generic Drug Industry Perspective
 
Prescription Drug Monitoring Program | State of California - Department of Ju...
Prescription Drug Monitoring Program | State of California - Department of Ju...Prescription Drug Monitoring Program | State of California - Department of Ju...
Prescription Drug Monitoring Program | State of California - Department of Ju...
 
Prescription Drug Monitoring Program | State of California - Department of Ju...
Prescription Drug Monitoring Program | State of California - Department of Ju...Prescription Drug Monitoring Program | State of California - Department of Ju...
Prescription Drug Monitoring Program | State of California - Department of Ju...
 
Pharma Uptoday MM: Volume 1 issue April 2014
Pharma Uptoday MM: Volume 1 issue April 2014 Pharma Uptoday MM: Volume 1 issue April 2014
Pharma Uptoday MM: Volume 1 issue April 2014
 
mobile medical applications
mobile medical applicationsmobile medical applications
mobile medical applications
 
Guidance for Industry and Food and Drug Administration Staff: Mobile Medical ...
Guidance for Industry and Food and Drug Administration Staff: Mobile Medical ...Guidance for Industry and Food and Drug Administration Staff: Mobile Medical ...
Guidance for Industry and Food and Drug Administration Staff: Mobile Medical ...
 
A) Study in detail about Para - IV filing. B) Case studies for Para - IV Filing.
A) Study in detail about Para - IV filing. B) Case studies for Para - IV Filing.A) Study in detail about Para - IV filing. B) Case studies for Para - IV Filing.
A) Study in detail about Para - IV filing. B) Case studies for Para - IV Filing.
 

Mais de Norman Gates

Cannabidiol treatment-ameliorates-acetaminophen-induced-hepatotoxicity-in-mice
Cannabidiol treatment-ameliorates-acetaminophen-induced-hepatotoxicity-in-miceCannabidiol treatment-ameliorates-acetaminophen-induced-hepatotoxicity-in-mice
Cannabidiol treatment-ameliorates-acetaminophen-induced-hepatotoxicity-in-mice
Norman Gates
 
Federal obstruction-of-mmj-research-1
Federal obstruction-of-mmj-research-1Federal obstruction-of-mmj-research-1
Federal obstruction-of-mmj-research-1
Norman Gates
 

Mais de Norman Gates (12)

Bitcoin ETF approval official documents.pdf
Bitcoin ETF approval official documents.pdfBitcoin ETF approval official documents.pdf
Bitcoin ETF approval official documents.pdf
 
Medical Marijuana Inc. Smear Campaign Lawsuit
Medical Marijuana Inc. Smear Campaign LawsuitMedical Marijuana Inc. Smear Campaign Lawsuit
Medical Marijuana Inc. Smear Campaign Lawsuit
 
Austism CBD
Austism CBDAustism CBD
Austism CBD
 
Settlement agreement en
Settlement agreement enSettlement agreement en
Settlement agreement en
 
Phot halt
Phot haltPhot halt
Phot halt
 
Cannabidiol treatment-ameliorates-acetaminophen-induced-hepatotoxicity-in-mice
Cannabidiol treatment-ameliorates-acetaminophen-induced-hepatotoxicity-in-miceCannabidiol treatment-ameliorates-acetaminophen-induced-hepatotoxicity-in-mice
Cannabidiol treatment-ameliorates-acetaminophen-induced-hepatotoxicity-in-mice
 
Ag holder-testimony
Ag holder-testimonyAg holder-testimony
Ag holder-testimony
 
Compplan
CompplanCompplan
Compplan
 
Us20100286993
Us20100286993Us20100286993
Us20100286993
 
HHS Doblin
HHS DoblinHHS Doblin
HHS Doblin
 
Federal obstruction-of-mmj-research-1
Federal obstruction-of-mmj-research-1Federal obstruction-of-mmj-research-1
Federal obstruction-of-mmj-research-1
 
420 Investor, Alan Brochstein CFA
420 Investor, Alan Brochstein CFA420 Investor, Alan Brochstein CFA
420 Investor, Alan Brochstein CFA
 

Último

Seal of Good Local Governance (SGLG) 2024Final.pptx
Seal of Good Local Governance (SGLG) 2024Final.pptxSeal of Good Local Governance (SGLG) 2024Final.pptx
Seal of Good Local Governance (SGLG) 2024Final.pptx
negromaestrong
 
Russian Escort Service in Delhi 11k Hotel Foreigner Russian Call Girls in Delhi
Russian Escort Service in Delhi 11k Hotel Foreigner Russian Call Girls in DelhiRussian Escort Service in Delhi 11k Hotel Foreigner Russian Call Girls in Delhi
Russian Escort Service in Delhi 11k Hotel Foreigner Russian Call Girls in Delhi
kauryashika82
 
The basics of sentences session 3pptx.pptx
The basics of sentences session 3pptx.pptxThe basics of sentences session 3pptx.pptx
The basics of sentences session 3pptx.pptx
heathfieldcps1
 

Último (20)

Micro-Scholarship, What it is, How can it help me.pdf
Micro-Scholarship, What it is, How can it help me.pdfMicro-Scholarship, What it is, How can it help me.pdf
Micro-Scholarship, What it is, How can it help me.pdf
 
Seal of Good Local Governance (SGLG) 2024Final.pptx
Seal of Good Local Governance (SGLG) 2024Final.pptxSeal of Good Local Governance (SGLG) 2024Final.pptx
Seal of Good Local Governance (SGLG) 2024Final.pptx
 
Food safety_Challenges food safety laboratories_.pdf
Food safety_Challenges food safety laboratories_.pdfFood safety_Challenges food safety laboratories_.pdf
Food safety_Challenges food safety laboratories_.pdf
 
How to Manage Global Discount in Odoo 17 POS
How to Manage Global Discount in Odoo 17 POSHow to Manage Global Discount in Odoo 17 POS
How to Manage Global Discount in Odoo 17 POS
 
Magic bus Group work1and 2 (Team 3).pptx
Magic bus Group work1and 2 (Team 3).pptxMagic bus Group work1and 2 (Team 3).pptx
Magic bus Group work1and 2 (Team 3).pptx
 
Mixin Classes in Odoo 17 How to Extend Models Using Mixin Classes
Mixin Classes in Odoo 17  How to Extend Models Using Mixin ClassesMixin Classes in Odoo 17  How to Extend Models Using Mixin Classes
Mixin Classes in Odoo 17 How to Extend Models Using Mixin Classes
 
SKILL OF INTRODUCING THE LESSON MICRO SKILLS.pptx
SKILL OF INTRODUCING THE LESSON MICRO SKILLS.pptxSKILL OF INTRODUCING THE LESSON MICRO SKILLS.pptx
SKILL OF INTRODUCING THE LESSON MICRO SKILLS.pptx
 
Dyslexia AI Workshop for Slideshare.pptx
Dyslexia AI Workshop for Slideshare.pptxDyslexia AI Workshop for Slideshare.pptx
Dyslexia AI Workshop for Slideshare.pptx
 
Grant Readiness 101 TechSoup and Remy Consulting
Grant Readiness 101 TechSoup and Remy ConsultingGrant Readiness 101 TechSoup and Remy Consulting
Grant Readiness 101 TechSoup and Remy Consulting
 
Russian Escort Service in Delhi 11k Hotel Foreigner Russian Call Girls in Delhi
Russian Escort Service in Delhi 11k Hotel Foreigner Russian Call Girls in DelhiRussian Escort Service in Delhi 11k Hotel Foreigner Russian Call Girls in Delhi
Russian Escort Service in Delhi 11k Hotel Foreigner Russian Call Girls in Delhi
 
UGC NET Paper 1 Mathematical Reasoning & Aptitude.pdf
UGC NET Paper 1 Mathematical Reasoning & Aptitude.pdfUGC NET Paper 1 Mathematical Reasoning & Aptitude.pdf
UGC NET Paper 1 Mathematical Reasoning & Aptitude.pdf
 
Unit-IV- Pharma. Marketing Channels.pptx
Unit-IV- Pharma. Marketing Channels.pptxUnit-IV- Pharma. Marketing Channels.pptx
Unit-IV- Pharma. Marketing Channels.pptx
 
General Principles of Intellectual Property: Concepts of Intellectual Proper...
General Principles of Intellectual Property: Concepts of Intellectual  Proper...General Principles of Intellectual Property: Concepts of Intellectual  Proper...
General Principles of Intellectual Property: Concepts of Intellectual Proper...
 
On National Teacher Day, meet the 2024-25 Kenan Fellows
On National Teacher Day, meet the 2024-25 Kenan FellowsOn National Teacher Day, meet the 2024-25 Kenan Fellows
On National Teacher Day, meet the 2024-25 Kenan Fellows
 
Application orientated numerical on hev.ppt
Application orientated numerical on hev.pptApplication orientated numerical on hev.ppt
Application orientated numerical on hev.ppt
 
The basics of sentences session 3pptx.pptx
The basics of sentences session 3pptx.pptxThe basics of sentences session 3pptx.pptx
The basics of sentences session 3pptx.pptx
 
Unit-V; Pricing (Pharma Marketing Management).pptx
Unit-V; Pricing (Pharma Marketing Management).pptxUnit-V; Pricing (Pharma Marketing Management).pptx
Unit-V; Pricing (Pharma Marketing Management).pptx
 
Third Battle of Panipat detailed notes.pptx
Third Battle of Panipat detailed notes.pptxThird Battle of Panipat detailed notes.pptx
Third Battle of Panipat detailed notes.pptx
 
microwave assisted reaction. General introduction
microwave assisted reaction. General introductionmicrowave assisted reaction. General introduction
microwave assisted reaction. General introduction
 
How to Create and Manage Wizard in Odoo 17
How to Create and Manage Wizard in Odoo 17How to Create and Manage Wizard in Odoo 17
How to Create and Manage Wizard in Odoo 17
 

DEA - More Marijuana

  • 1. This document is scheduled to be published in the Federal Register on 05/05/2014 and available online at http://federalregister.gov/a/2014-10202, and on FDsys.gov BILLING CODE 4410-09-P 1 DEPARTMENT OF JUSTICE Drug Enforcement Administration [Docket No. DEA–378] Controlled Substances: Adjustment to the Established 2014 Aggregate Production Quota for Marijuana AGENCY: Drug Enforcement Administration, Department of Justice. ACTION: Notice with request for comments. SUMMARY: This notice adjusts the established 2014 aggregate production quota for marijuana, a schedule I controlled substance under the Controlled Substances Act. DATES: Effective date: [INSERT DATE OF PUBLICATION IN THE FEDERAL REGISTER]. Comment date: Interested persons may file written comments on this notice in accordance with 21 CFR 1303.13. Electronic comments must be submitted and written comments must be postmarked, on or before [INSERT DATE 30 DAYS AFTER DATE OF PUBLICATION IN THE FEDERAL REGISTER]. Commenters should be aware that the electronic Federal Docket Management System will not accept comments after midnight Eastern Time on the last day of the comment period. ADDRESSES: To ensure proper handling of comments, please reference “Docket No. DEA–378” on all electronic and written correspondence. The DEA encourages that all comments be submitted electronically through the Federal eRulemaking Portal which provides the ability to type short comments directly into the comment field on the Web page or attach a file for lengthier comments. Please go to http://www.regulations.gov and follow the online instructions at that site for submitting comments. Paper comments that duplicate electronic submissions are not necessary. Should you, however, wish to
  • 2. 2 submit written comments, in lieu of electronic comments, they should be sent via regular or express mail to: Drug Enforcement Administration, Attention: DEA Federal Register Representative/ODXL, 8701 Morrissette Drive, Springfield, Virginia 22152. FOR FURTHER INFORMATION CONTACT: Ruth A. Carter, Office of Diversion Control, Drug Enforcement Administration; Mailing Address: 8701 Morrissette Drive, Springfield, Virginia 22152, Telephone: (202) 598–6812. SUPPLEMENTARY INFORMATION: Posting of Public Comments Please note that all comments received in response to this docket are considered part of the public record and will be made available for public inspection online at http://www.regulations.gov. Such information includes personal identifying information (such as your name, address, etc.) voluntarily submitted by the commenter. The Freedom of Information Act (FOIA) applies to all comments received. If you want to submit personal identifying information (such as your name, address, etc.) as part of your comment, but do not want it to be made publicly available, you must include the phrase “PERSONAL IDENTIFYING INFORMATION” in the first paragraph of your comment. You must also place all of the personal identifying information you do not want made publicly available in the first paragraph of your comment and identify what information you want redacted. If you want to submit confidential business information as part of your comment, but do not want it to be made publicly available, you must include the phrase “CONFIDENTIAL BUSINESS INFORMATION” in the first paragraph of your comment. You must also prominently identify the confidential business information to be redacted within the comment. If a comment has so much
  • 3. 3 confidential business information that it cannot be effectively redacted, all or part of that comment may not be made publicly available. Comments containing personal identifying information or confidential business information identified as directed above will be made publicly available in redacted form. An electronic copy of this document is available at http://www.regulations.gov for easy reference. If you wish to personally inspect the comments and materials received or the supporting information the DEA used in preparing this action, these materials will be available for public inspection by appointment. To arrange a viewing, please see the “For Further Information Contact” paragraph above. Pursuant to 21 CFR 1303.13, any interested person may submit written comments on or objections to this notice. Based on comments received in response to this notice, the Administrator may hold a public hearing on one or more issues raised in the comments and objections filed. In the event the Administrator decides to hold such a hearing, the Administrator shall publish notice of the hearing in the Federal Register. After consideration of any comments or objections, or after a hearing, if one is held, the Administrator shall issue and publish in the Federal Register a notice regarding the adjustment to the established 2014 aggregate production quota for marijuana.1 Legal Authority The Drug Enforcement Administration (DEA) implements and enforces titles II and III of the Comprehensive Drug Abuse Prevention and Control Act of 1970, as amended. Titles II and III are referred to as the “Controlled Substances Act” and the “Controlled Substances Import and Export Act,” respectively, and are collectively referred to as the 1 Note that "marihuana" is the spelling originally used in the Controlled Substances Act (CSA). This document uses the spelling that is more common in current usage, "marijuana."
  • 4. 4 “Controlled Substances Act” or the “CSA” for the purpose of this action. 21 U.S.C. 801– 971. The DEA publishes the implementing regulations for these statutes in title 21 of the Code of Federal Regulations (CFR), parts 1300 to 1321. The CSA and its implementing regulations are designed to prevent, detect, and eliminate the diversion of controlled substances and listed chemicals into the illicit market while providing for the legitimate medical, scientific, research, and industrial needs of the United States. Controlled substances have the potential for abuse and dependence and are controlled to protect the public health and safety. Section 306 of the CSA (21 U.S.C. 826) requires the Attorney General to establish aggregate production quotas for each basic class of controlled substance listed in schedules I and II each year. The Attorney General has delegated this authority under 21 U.S.C. 826 to the Administrator of the DEA, 28 CFR 0.100. Background The DEA established the initial 2014 aggregate production quotas and assessments for annual need on September 9, 2013 (78 FR 55099). The notice stipulated that, as provided for in 21 CFR 1303.13, all aggregate production quotas and assessments for annual need are subject to adjustment. Analysis for Adjusting the Established 2014 Aggregate Production Quota for Marijuana Effective on the Date of Publication In determining to adjust the aggregate production quota, the DEA takes into consideration, among other factors, the relevant scientific and research needs of the United States. 21 U.S.C. 826; 21 CFR 1303.13(b)(5).
  • 5. 5 The National Institute on Drug Abuse (NIDA) is a component of the National Institutes of Health and the U.S. Department of Health and Human Services, and it oversees the cultivation, production and distribution of research-grade marijuana on behalf of the United States Government, pursuant to the Single Convention on Narcotic Drugs (March 30, 1961, 18 UST 1407). NIDA recently notified the DEA that it required additional supplies of marijuana to be manufactured in 2014 to provide for current and anticipated research efforts involving marijuana. Specifically, NIDA stated that 600 kilograms is necessary to be manufactured in 2014. The DEA was unaware of NIDA’s additional need at the time the initial aggregate production quota for marijuana was established in September 2013. The aggregate production quota for marijuana should be increased in order to provide a continuous and uninterrupted supply of marijuana in support of DEA-registered researchers who are approved by the Federal Government to utilize marijuana in their research protocols. In the event the established aggregate production quota is increased, DEA regulations require general notice of the adjustment prior to adjusting the quota. 21 CFR 1303.13(c). Due to the manufacturing process unique to marijuana, including the length of time and conditions necessary to propagate and process the substance for distribution in 2014, it is necessary to adjust the initial, established 2014 aggregate production quota for marijuana as soon as practicable. Accordingly, the Administrator finds good cause to adjust the aggregate production quota for marijuana before accepting written comments from interested persons or holding a public hearing, pursuant to 21 CFR 1303.13(c). More specifically, the Administrator finds, based on NIDA's aforementioned submission to
  • 6. 6 DEA, that it is in the public interest to adjust the aggregate production quota immediately to ensure that the cultivation of marijuana to meet NIDA's anticipated needs to supply researchers can proceed within the current grow cycle. For this same reason, the Administrator finds that delaying the adjustment to the aggregate production quota for marijuana until after the comment period would be impracticable. Any such comments shall be considered if submitted in accordance with the procedures described herein. In issuing this adjustment, the DEA has taken into account the criteria that the DEA is required to consider in accordance with 21 CFR 1303.13(b). The DEA determines whether to adjust the aggregate production quotas for basic classes of schedule I and II controlled substances by considering: (1) changes in demand for the basic class, changes in the national rate of net disposal for the class, and changes in the rate of net disposal by the registrants holding individual manufacturing quotas for the class; (2) whether any increased demand or changes in the national or individual rates of net disposal are temporary, short term, or long term; (3) whether any increased demand can be met through existing inventories, increased individual manufacturing quotas, or increased importation, without increasing the aggregate production quota; (4) whether any decreased demand will result in excessive inventory accumulation by all persons registered to handle the class; and (5) other factors affecting the medical, scientific, research, and industrial needs of the United States and lawful export requirements, as the Administrator finds relevant. Based on the above, the Administrator adjusts the established 2014 aggregate production quota for marijuana, to be manufactured in the United States in 2014 to provide for the estimated scientific, research, and industrial needs of the United States,
  • 7. 7 and the establishment and maintenance of reserve stocks, expressed in grams of anhydrous acid or base, as follows: Basic Class-Schedule I Previously Established 2014 Quota Adjusted 2014 Quota Marijuana 21,000 g 650,000 g Dated: April 29, 2014. Michele M. Leonhart, Administrator. [FR Doc. 2014-10202 Filed 05/02/2014 at 8:45 am; Publication Date: 05/05/2014]